Specialty Pharmacy

Tofacitinib citrate (Xeljanz) is the first and only once-daily oral Janus kinanse inhibitor for the treatment of moderate-to-severe RA.

Tofacitinib citrate (Xeljanz) is an extended-release tablet for patients with moderate-to-severe rheumatoid arthritis.

Approximately 40% of the elderly and nearly 11% of the US population take 5 or more prescription drugs.

Specialty pharmacy automatic refill programs weigh improved adherence versus medication oversupply.

CRISPR/Cas9 gene editing platform able to remove Duchenne mutations in cells.

Study finds cancer patients need better support following treatment.

Research seeks to determine the genetic and environmental risk factors that trigger MS.

Strong evidence suggests increased risk for respiratory, cardiovascular, and overall mortality for patients with RA.

Psoriatic arthritis patients who achieve persistent minimal disease activity more likely to experience long-term improvement with golimumab.

Formulary adjustments by the pharmacy benefit manager limited prescription drug spending jump to 5 percent.

The most commonly used biologic drugs to treat RA include etanercept, adalimumab, infliximab, and abatacept

Health care plans that improve the quality of care may see higher updates and enhance benefits for enrollees.

Specialty benefit design and management tools can ensure optimal patient care.

Price inflation in non-specialty drug brands outweighed all other prescription medication trend drivers.

Dasatinib and demcizumab reduces lung adenocarcinomas and improves survival rates in lung cancer treatment.

Nanoparticle designed to directly hit tumors with a toxic cancerous drug without harming healthy tissue.

New HIV treatment approach scrambles DNA to stop it from multiplying.

Gut microbiota poses a curious question in MS development and research.

Pharmacists can play a role in a comprehensive geriatric assessment and transitional care bridge program to improve outcomes for older adults.

Palbociclib (Ibrance) approved for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Ibrance approved for the treatment of HR+, HER2- advanced or metastatic breast cancer.

Elamipretide targets the inner mitochondrial membrane and helps preserve mitochondrial energetics in patients with primary mitochondrial myopathy.

Antibody-drug conjugates and immunotherapy harness immune system to target breast cancer tumors.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how specialty pharmacies can leverage technology to improve the consumer experience.

Hysterectomies can reduce the risk for ovarian cancer but it can lead to surgical menopause.

Researchers explore possible reasons why HIV-positive patients have a decreased risk of MS.

Treatments approved for heart failure, cardiac arrhythmia, and infections offer epigenetic effects in cancer therapy.

Most read articles of the week on The American Journal of Pharmacy Benefits.